Dear consumers:

Sichuan Baili Pharma Co.,Ltd revised and put the revised instructions of its Ribavirin Granules (Specification: 50mg; Approval No.: H51023508; Specification: 0.1g, Approval No.: H51023509; Specification: 0.15g, Approval No.: H51023510) on file in accordance with National Medical Products Administration’s Announcement on Revision of the Instructions of Ribavirin Preparation for Systemic Use (No. 55 of 2023, see Annex 1).

To ensure proper use of medication, we have updated the revised instructions on the website of Sichuan Biokin Pharmaceutical Co.,Ltd and GS1 China. The users can obtained the new instructions via these two channels (see Annex 2 for operation procedures). Please use the medication in accordance with the revised instructions and pay attention to the potential adverse reactions, so as to ensure medication safety.

Sichuan Baili Pharma Co., Ltd

January 13, 2025